Navigation Links
Proteolix Presents Preclinical Data for Oral Proteasome Inhibitor PR-047 at the 50th Annual Meeting of the American Society of Hematology
Date:12/8/2008

Lead Oral Candidate Demonstrates Proteasome Inhibition and Anti-Tumor Activity

SOUTH SAN FRANCISCO, Calif., Dec. 8 /PRNewswire/ -- Proteolix, Inc., today announced results from a series of in vitro and in vivo studies designed to characterize PR-047, the company's oral proteasome inhibitor. These data were presented today in a poster titled "Preclinical Pharmacology and In Vitro Characterization of PR-047, An Oral Inhibitor of the 20S Proteasome" (Abstract # 3671) at the 50th Annual Meeting of the American Society of Hematology (ASH). PR-047 is the first oral compound in a new class of highly specific proteasome inhibitors. Carfilzomib, the lead compound in this class, will be the subject of two oral presentations of Phase 2 data on Tuesday, December 9th. PR-047 was designed by Proteolix scientists to combine the pharmacological properties of carfilzomib with the convenience of oral dosing.

Researchers evaluated PR-047's mechanism, bioavailability and activity in a series of preclinicalstudies. Like carfilzomib, PR-047 was shown to target the chymotrypsin-like activity of the proteasome and induce tumor cell death across multiple human cell lines. Oral administration of PR-047 in rodents and monkeys resulted in rapid and prolonged dose-dependent inhibition of the proteasome. Furthermore, significant proteasome inhibition was achieved at doses well below the maximum-tolerated dose even when administered over five consecutive days, suggesting that repeated daily dosing may be feasible with this molecule. Administration of PR-047 resulted in consistent anti-tumor responses in hematological and solid tumor xenograft models at doses below the maximum-tolerated dose.

"We are pleased by the preclinical data achieved to date with PR-047, which demonstrates a promising combination of proteasome inhibition, anti-tumor activity, bioavailability and tolerability," said Mark Bennett, Ph.D., Vice President of Research at Proteolix. "An effective and tolerable oral proteasome inhibitor would have the potential to provide the clinical benefits of intravenous proteasome inhibitors with added patient convenience and dosing flexibility. With these positive preclinical results in hand, we look forward to advancing PR-047 into clinical trials."

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of highly specific proteasome inhibitors, and is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor (PR-047) and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.

    Contact information
    Investors:                          Media Inquiries:
    Matthew Ferguson                    BCC Partners
    Chief Financial Officer             Karen L. Bergman or Michelle Corral
    650-266-2825                        650-575-1509 or 415-794-8662
    investors@proteolix.com


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Proteolix Raises $79 Million in Series C Financing
2. Proteolixs Carfilzomib Receives Orphan Drug Designation for Treatment of Multiple Myeloma
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Frost & Sullivan Presents CorMatrix Cardiovascular Inc. with 2008 Healthcare Innovation Award for the Treatment of Cardiovascular Disease
5. AmeriCares Presents Power of Partnership Award to Baxter
6. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
7. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
10. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
11. GeoVax Presents Data at AIDS Vaccine 2008 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company developing ... MPH, will present information about the company,s programs at the BIOCEO ... New York City . --> ... 5:30PM EST. Registered attendees can request a one on one meeting ... --> New York City . ...
(Date:2/8/2016)... -- --> --> ... ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it ... test to be launched on the Company,s io® platform. By ... test is now cleared for sale within the European Union. ... of the io® CT test signals a new era in ...
(Date:2/5/2016)... , Feb. 5, 2016 ATCC, the ... poised to assist the medical and life science researchers ... Zika Virus infection.   CDC website . ... --> Zika virus is a single-stranded RNA virus ... the West Nile, Dengue and Chikungunya Viruses. Zika virus ...
(Date:2/5/2016)... SAN FRANCISCO , February 5, 2016 ... AMBS), a biotechnology company focused on developing products ... it has requested Rare Pediatric Disease Designation (RPDD) from ... retinitis pigmentosa (RP) with MANF. MANF was previously granted ... December 2014. --> Amarantus BioScience Holdings, Inc. ...
Breaking Biology Technology:
(Date:2/3/2016)... , Feb. 3, 2016 ... the addition of the "Emotion Detection ... Machine Learning, and Others), Software Tools (Facial ... Areas, End Users,and Regions - Global forecast ... --> http://www.researchandmarkets.com/research/d8zjcd/emotion_detection ) has ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/2/2016)... , Feb. 2, 2016  Based on ... Frost & Sullivan recognizes US-based Intelligent Retinal Imaging ... & Sullivan Award for New Product Innovation. IRIS, ... North America , is poised ... rapidly growing diabetic retinopathy market. The IRIS technology ...
Breaking Biology News(10 mins):